ULURU, Inc.

Neuro20 Technologies becomes the first US-based company to produce an FDA-cleared medical electrical muscle stimulation textile that closes the loop between diagnostics and interventions in a wireless operating system TAMPA, Fla., March 2, 2023 /PRNewswire/ -- Neuro20 Technologies Corp, a wearable medical device manufacturing company specializing in the development of next-generation wireless wearable textiles to treat neuromuscular injuries and disease while enhancing human performance outcomes, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's 510(k) pre-market approval application for its Neuro20 PRO System. A first-of-its-kind wearable, the Neuro20 PRO System Whole-Body Electrical Muscle Stimulator Suit, Software and Operating System involuntarily contracts 42 muscles independently or by any combination of co-contraction, with control specificity for each muscle for 1 to 10 patients at a time. "Neuro20 Technologies has solved the greatest roadblock in rehabilitation: correcting old habits that were formed in response to old injuries," said Dr. Davis W. Brockenshire, D.C., of Innovative Health Solutions, a Michigan-based practice that specializes in advanced functional medicine. "The ability to retrain corrective movement patterns without injury or exhaustion allows the client to achieve a freedom of performance otherwise unattainable. I personally use the Neuro20 PRO System to re-acquire and maintain optimal movement patterns due to injuries sustained over a lifetime of athletic competitions." The Neuro20 PRO System's Suit has large-contoured electrodes to cover maximum motor neuron activation, distinguishing it from current electrical muscle stimulation systems on the market. The Neuro20 PRO System has four programs and nine sub-modes for strength and recovery, including proprietary PEMS (Patterned Electrical Muscle Stimulation) programs that involuntarily contract muscles throughout the motor chain replicating specified patterns of movement while the patient attempts to create a voluntary override of the movement. Electrical stimulation results demonstrate up to a 20% increase in Maximum Voluntary Contraction, up to 30% vascular dilation, and an increase in BDNF (brain-derived neurotrophic factor) between 18%-30%, depending on gene expression. The FDA cleared the Neuro20 PRO System for the following Indications for Use: Muscle Re-education, Increasing Local Blood Circulation, Maintaining or Increasing Range of Motion, Relaxation of Muscle Spasms, Reduction or Prevention of Muscle Atrophy. "FDA clearance of our Neuro20 PRO System to treat neuromuscular injury and disease is a significant milestone for Neuro20 Technologies as we prepare to educate the market about the benefits of this technological advancement," said Dennis M. Schmitt, Chief Executive Officer of Neuro20 Technologies. "Our pioneering approach to physical rehabilitation has the potential to benefit patients significantly. We are pleased to disrupt current industry practices in electrical stimulation therapy by providing safe, affordable, result-driven outcomes for providers and patients suffering from neuromuscular injury and disease. The Neuro20 PRO system is the reconceptualization of electrical muscle stimulation to make it more efficient for both provider and patient. The FDA clearance will launch electroceutical medicine forward in the 21st century, and we are excited to reframe the possibilities in this field by working with providers to demonstrate this new, efficient technology." About Neuro20 Technologies Corp. Neuro20 Technologies was founded in 2021 and is a registered Delaware Corp located in Tampa, Florida. Neuro20 Technologies is located in the "Research and Innovation" building at the University of South Florida, USF CONNECT, and is a member of the Tampa Bay Technology Incubator. Neuro20 Technologies focuses on transforming health through scientific research-based practices utilizing Electrical Muscle Stimulation (EMS). We are proud to be led by a team of experts with knowledge expanding across many disciplines, with the collective goal of modernizing how technology is used to promote recovery and human performance. Forward-Looking Statements This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our Neuro20 PRO System; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of injuries and diseases; the timing, conduct and success of our clinical products, our ability to use our manufacturing facilities to support clinical and commercial demand; and our future operating expenses and capital expenditure requirements. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at . The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Investor Contact: Harvard Business School Alumni Angels Christian Schweitzer presidentaa@hbssouthflorida.org Media Contact: Michael Finkelstein Neuro20 Technologies 917-503-6876 354776@email4pr.com

RESTON, Va., Aug. 14, 2017 /PRNewswire/ -- Leidos (NYSE: LDOS), a FORTUNE 500® science and technology company, has signed a Memorandum of Understanding  (MOU) with Biosortia Pharmaceuticals to explore creating a new business relationship with a focus on identifying and advancing immuno-oncology and other immunotherapeutic opportunities. Both companies offer existing and future assets in the immunotherapeutic space that will enable them to deliver de-risked assets to a future pharmaceutical partner for development. The companies' assets include compounds derived from microbiome sources, screening assays, and scientific expertise that will focus on moving assets to investigational new drug clinical research for development by the partner. Technologies involved include Biosortia's proprietary microbiome harvesting and mining capabilities and Leidos' big data analytics.  Leidos has advanced various immune checkpoint inhibitor peptides that provide unique differentiation from the current therapeutic monoclonal antibodies. When coupled with Leidos' data analytics technologies and capabilities and Biosortia's harvesting and mining technologies, these assets represent a unique opportunity to accelerate the process of identifying and maturing a new class of immunotherapies.  "The high cost of de-risked assets due to the dismal success rates of combinatorial chemistry and the ever-emerging complexities of genomics has encouraged us to pursue a unique and validated approach," said Ross Youngs, Chief Executive Officer of San Diego-based of Biosortia Pharmaceuticals "We have created technologies to deeply explore various microbiome habitats for new cell to cell signaling, which is more closely related to previously successful drug discovery approaches via culturing, that have delivered directly, indirectly or inspirational more than 50% of drugs on the shelf." "Combining deep analytics and genomics with novel chemistry from the microbiome provides a platform to uncover and create the next generation of immunological drugs," added Matt Vaughan, Senior Vice President of Health Products and Solutions in the Leidos Health Group.  About Biosortia Pharmaceuticals, Inc. Biosortia was founded in 2012 and is a private, closely held Delaware C-Corp based in San Diego with a focus on immuno-oncology, and immunological therapeutics discovered by a unique access to previously unobtainable natural chemistry in the various microbiome with a focus on delivering new opportunities into drug development. Deep access to previously unobtainable drug like natural chemistry from the microbiome for the cell to cell signaling is key to many opportunities to cure or treat disease.  About Leidos Leidos is a FORTUNE 500® science and technology solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, homeland security, civil and health markets. The company's 32,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $7.04 billion for the fiscal year ended December 30, 2016. For more information, visit . Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10Q for the quarterly period ended June 30, 2017 and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Contacts: Jennifer Moffett, Jennifer.a.moffett@leidos.com   Chad Hummell, chummell@biosortia.com   View original content: SOURCE Leidos

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today! ADDISON, Texas, Aug. 9, 2013 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR) today announced that it has scheduled a conference call to discuss the second quarter ended June 30, 2013 financial results and to provide a general business update on Thursday, August 15, 2013 at 9:00 a.m. Eastern Time. To participate in the conference call please dial (800) 357-0498, for international callers dial (850) 429-1388 (access code 24013#) five to ten minutes prior to the initiation of the teleconference. If you are unable to listen to the live broadcast, a replay of the call will be available starting on August 15, 2013 two hours following the end of the call until August 29, 2013 at 11:59 p.m. Eastern Time. For the U.S. replay, please dial (866) 415-9493 and international callers please dial (205) 289-3247 (access code 24013#). You may also access the replay of the call two hours following the end of the call until August 29, 2013 at 11:59 p.m. Eastern Time via the web by logging onto . About ULURU Inc.: ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers with improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc transmucosal delivery system. For more information about ULURU Inc., please visit . For more information about Altrazeal®, please visit . This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and other reports filed by us with the Securities and Exchange Commission. Contact: Company Kerry P. Gray President & CEO Terry K. Wallberg Vice President & CFO (214) 905-5145 SOURCE ULURU Inc. Hey, check out all the engineering jobs. Post your resume today!